The Effect of Mediclore as an Anti-adhesion Agent and Safety in Full-endoscopic Spine Surgery: a Preliminary Study

Sponsor
King Chulalongkorn Memorial Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06034041
Collaborator
(none)
78
1
2
8
9.7

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare efficacy and safety of Mediclore as anti-adhesion agent in patient who undergo endoscopic lumbar discectomy. The main question[s] it aims to answer are:

  • efficacy (patient-reported outcomes, epidural fibrosis)

  • safety (complications) Participants will received Mediclore at surgical site after finish the operation in experimental group and normal saline in control group.

Researchers will compare to see if experimental group have better patient-reported outcomes (PROs) after surgery with no different in complications rate.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

This study is a randomized clinical trial arrange in King Chulalongkorn Memorial Hospital. Participant will be randomly assigned into 2 groups by computer-generated sequence. Patients based-line characteristic data, patient-reported outcomes (VAS back/leg, ODI and EQ-5D) and a results of straight leg raising test will be collected. Participant will undergo a endoscopic lumbar discectomy by a singer spine surgeon. In experimental group, 1.5 CC. of Mediclore (poloxamer-based thermosensitive anti-adhesive agent) will be applied in after finish the operation. In control group normal saline 1.5 CC. will be applied instead.

Participants will proceed to regular follow-up protocol which include 1, 3 and 6 months visit at out-patient department. All of the PROs and a result of a straight leg raising test will be collected at each visit. MRI will be performed at 3 month after the surgery. The amount of epidural fibrosis will be evaluated according to Ross's method.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
78 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effect of Mediclore as an Anti-adhesion Agent and Safety in Full-endoscopic Spine Surgery: a Preliminary Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mediclore

After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.

Drug: Mediclore
After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.

Placebo Comparator: Control

After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.

Drug: Normal Saline
After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
Other Names:
  • Control
  • Outcome Measures

    Primary Outcome Measures

    1. Visual Analogue Score for Leg pain (VAS Leg) [3 month after surgery]

      The VAS Leg consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('the worst pain in a lifetime'). The patient was asked to rate their current pain level by pointing the mark on the line.

    Secondary Outcome Measures

    1. Visual Analogue Score for Leg and Back pain (VAS Leg, Back) [1, 3 and 6 month after surgery (for VAS Back) and 1 and 6 month after surgery (for VAS Leg)]

      The VAS Leg and Back consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('the worst pain in a lifetime'). The patient was asked to rate their current pain level by pointing the mark on the line.

    2. Oswestry Disability Index (ODI) [1, 3 and 6 month after surgery]

      The ODI consists of 10 questions to assess the function in daily activities living, in which the responses are presented as 6-point Likert scales. Scores range from 0% (no disability) to 100% (most severe disability).

    3. EQ-5D-5L [1, 3 and 6 month after surgery]

      The EQ-5D-5L has 2 parts. In the first part, consist of 5 questions to assess the function in daily activities living, in which the responses are presented as 5 level (1 means no problems to 5 means extreme problems). The digits for the five questions can be combined into a 5-digit number that describes the patient's health state. The results will interpreted with the country specific utility score (Thailand) and reported as three decimal digit range from 0 (the worst health you can imagine) to 1 (the best health you can imagine).

    4. Epidural Fibrosis [3 month after surgery]

      Evaluation of epidural fibrosis by method proposed by Ross et al (1999) by MRI. From MRI axial cut, A surgical intervertebral level will be marked as level 3, 2 adjacent cephalic image will be marked as level 1 and 2. 2 adjacent caudad level will be marked as level 4 and 5. Then each image will be separated into 4 quadrant. Fibrosis will be graded on a scale of 0-4 for each quadrant at each imaging slice encompassing the operative level: 0 = no/trace scar; 1 = > 0-25% of quadrant filled with scar; 2 = 25-50% of quadrant filled with scar; 3 = 50-75% of quadrant filled with scar; 4 = > 75% of quadrant filled with scar. The highest grade of epidural fibrosis from any image will represent the degree of epidural ficrosis.

    5. Complication rate [peri-operation, 1, 3 and 6 month after surgery]

    6. Straight leg raising test [1, 3 and 6 month after surgery]

      Straight leg raising test will be performed at each visit. Results will be recorded as negative or positive. If positive, the degree that make a test positive will be also recorded.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Lumbar disc herniated patients

    • Failed proper conservative treatment more than 6 months

    Exclusion Criteria:
    • Previous history of lumbar spine surgery OR lumbar epidural steroid injection

    • Infection OR malignancy

    • Allergic to any given components

    • Lactation and pregnency

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 King Chulalongkorn Memorial Hospital Pathum Wan Bangkok Thailand 10330

    Sponsors and Collaborators

    • King Chulalongkorn Memorial Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Nattapat Tangchitcharoen, Clinical Fellow in Spine Surgery, Chulalongkorn University, King Chulalongkorn Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT06034041
    Other Study ID Numbers:
    • 66
    First Posted:
    Sep 13, 2023
    Last Update Posted:
    Sep 14, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 14, 2023